Andrzej Rys, Tabinda Dugal; Royal Cornwall Hospital, Truro, United Kingdom



Abstract

patients undergoing RNY gastric bypass procedures.

The prevalence of the type 2 diabetes and obesity are on the rise globally. Initial interventions for these groups of patients remain diet, exercise and medications. If these measures are insufficient gastrointestinal surgery offers a very good alternative for obesity and type 2 diabetes treatment.

We report the outcome results for patients who underwent either adjustable gastric banding (AGB) or Roux-en-Y (RNY) gastric bypass in the years 2009-2012.

Out of 33 patients (7 men, 26 women, average age 48.4 yrs), 11 underwent AGB and 22 had RNY. Preoperatively there were no statistically significant differences in: weight, excess of weight, Body Mass Index (BMI), HbA1c, blood pressure between AGB and RNY subgroups.

In the AGB subgroup the following results were obtained 6 months after the operation: average loss of weight (LOW) 10.87 kg, 18.18 % achieved 50% estimated weight loss (EWL), 0 % achieved 70% EWL. We observed HbA1c reduction of 5.66 mmol/mol. 12 months after the operation average LOW was 14.8 kg, 9.09 % achieved 50% EWL, 0 % achieved 70% EWL. We observed HbA1c reduction of 7.41 mmol/mol and reduction in BP of 9.6/5.6 mmHg.

In the RNY subgroup 6 months after operation the results were as follows: average LOW 30.9 kg, 71.43 % achieved 50% EWL, 23.81 % achieved 70% EWL. We observed HbA1c reduction of 24.1 mmol/mol.

12 months after the operation average LOW was 39.95 kg, 100 % achieved 50% EWL, 58.33 % achieved 70% EWL. We observed HbA1c reduction of 13.27 mmol/mol. We observed overall reduction in BP 12.5/4.95 mmHg The results show significantly better achievement of EWL and reduction in HbA1c in the RNY subgroup. These results were more sustainable in RNY group 12 months after the operation. Our report supports the more favourable outcomes in

Introduction

Obesity [body mass index (BMI) \geq 30 kg/m²] [1,2], is associated with increased risks of type 2 diabetes, stroke, ischaemic heart disease, liver disease, cancers, osteoarthritis, obstructive sleep apnoea and depression. Initial interventions for patients with obesity remain diet, exercise and medications. If these medical and behavioural approaches are insufficient there is a role for bariatric surgical procedures which become increasingly common worldwide [3].

Group characteristics (Pre-operatively)


33 patients (7 males, 26 females) Bariatric surgery in years 2009-2012 (AGR or RNY)


Danathe Surgery in years 2009-2012 (AGD of Kivi)				
		AGB	RNY	AGB + RNY
	Number of patients	11	22	33
Average	Age [years]	53.09	46.09	48.4
	Weight [kg]	120.94	121.72	121.46
	Weight excess [kg]	50.2	52.6	51.8
	BMI [kg/m ²]	42.86	44.63	44.04
Avarage values Pre-operatively	Systolic blood pressure (SBP) [mmHg]	136.4	140.2	138.3
	Diastolic blood	80.6	83.9	82.2
	pressure (DBP)			
	[mmHg]			
	HbA1c [mmol/mol]	58.3	62.9	61.42
	HbA1c [%]	7.49	7.9	7.77

We report the outcome results for patients who underwent either adjustable gastric banding (AGB) or Roux-en-Y (RNY) gastric bypass in the years 2009-2012.


RESULTS

6 months after surgery				
Average		AGB	RNY	AGB + RNY
	Weight [kg]	110.06	90.63	96,9
	Weight loss [kg]	10.87	30.9	24.3
	BMI [kg/m ²]	39.04	32.92	34.9
	50% estimated weight	18.18	71.4	53.1
	loss (EWL) achieved [%]			
	70% EWL achieved [%]	0	23.81	15.6
	HbA1c [mmol/mol]	52.64	38.8	47.96
	HbA1c [%]	6.96	6.21	6.53







12 months after surgery					
		AGB	RNY	AGB + RNY	
	Weight [kg]	106.05	82.87	93.78	
	Weight loss [kg]	14.88	39.35	28.8	
<u>0</u>	BMI [kg/m ²]	37.59	30.26	33.62	
Average	50% EWL achieved [%]	9.09	100	58.3	
<	70% EWL achieved [%]	0	58.33	37.5	
	HbA1c [mmol/mol]	50.89	49.78	50.3	
	HbA1c [%]	6.8	6.72	6.76	




Following bariatric surgical operations we observed improvement in both HbA1c and blood pressure measurements.

HbA1c and BP improvement after surgery				
	AGB	RNY	AGB + RNY	
6 months				
HbA1c [mmol/mol] reduction	5.66	24.1	13.46	
12 months				
HbA1c [mmol/mol] reduction	7.41	13.13	11.09	
BP after operation				
SBP [mmHg] reduction	9.6	12.5	11.5	
DBP [mmHg] reduction	5.6	4.95	4.2	
	6 months HbA1c [mmol/mol] reduction 12 months HbA1c [mmol/mol] reduction BP after operation SBP [mmHg] reduction	6 months HbA1c [mmol/mol] reduction 5.66 12 months HbA1c [mmol/mol] reduction 7.41 BP after operation SBP [mmHg] reduction 9.6	6 months HbA1c [mmol/mol] reduction 5.66 24.1 12 months HbA1c [mmol/mol] reduction 7.41 13.13 BP after operation SBP [mmHg] reduction 9.6 12.5	





Bariatric surgery enabled some of the patients to discontinue treatment for their diabetes, blood pressure and lipid profile. Patients in RNY subgroup were able to discontinue significantly more medications comparing with AGB subgroup.



Discontinued medications after surgery				
of nt		AGB	RNY	AGB + RNY
Average number of medications/patient	Discontinued medications for DM	0.64	1.41	1.15
	Discontinued medications for BP	0.27	0.41	0.36
	Discontinued medications for lipid control	0.09	0.09	0.09

Discussion

Our results support bariatric surgery as a beneficial procedure in management of patients with obesity and diabetes when medical and behavioural approaches prove insufficient. This is concordant with reports from other authors [4, 5, 6].

Our results show significantly better outcomes in the RNY subgroup in achievement of EWL, reduction in HbA1c and systolic blood pressure. These results are also more sustainable in RNY group 12 months after the operation. RNY subgroup patients were able to discontinue significantly more medications taken prior to operation, especially for diabetes and blood pressure control, when compared with AGB subgroup. This particular outcome has significant impact on the life long savings on medications cost. Our report supports the more favourable outcomes in patients undergoing Roux-en-Y (RNY) gastric bypass procedures compared with adjustable gastric banding (AGB).

References:

- 1. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obes Res 1998; 6 Suppl 2:51S.
- 2. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894:i.
- 3. Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg 2013; 23:427.
- 4. Health-related Quality of Life Changes and Weight Reduction After Bariatric Surgery vs. a Weight-loss Program. Canetti L, Elizur Y, Karni Y, M Berry E, Isr J Psychiatry Relat Sci. 2013;50(3):194-200. 5. A holistic assessment of bariatric surgical outcomes in a Northern Irish cohort. Neff KJ, Prener C, Chuah LL, O'Donnell K, Godsland IF, Miras AD, le Roux CW. Ir Med J. 2014 Jan; 107(1):24-6.
- 6. Long-term outcomes after bariatric surgery: fifteen-year follow-up of adjustable gastric banding and a systematic review of the bariatric surgical literature. O'Brien PE1, MacDonald L, Anderson M, Brennan L, Brown WA. Ann Surg. 2013 Jan; 257(1):87-94.